← Back to all signals
RESEARCH PAPER ANALYSIS

Identification of high-risk age groups for cisplatin-induced nausea and vomiting in young patients with sarcoma.

AI interpretation is pending for this paper.

Open original publication →
PMID41023770
JournalJournal of pharmaceutical health care and sciences
Publication Date2025-09-29
Ingested2026-08-02 12:05 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Young age has been reported as a patient-related risk factor for chemotherapy-induced nausea and vomiting (CINV). However, there have been few reports of the status of CINV limited to younger patients. In this study, CINV status after cisplatin administration was investigated in young patients with sarcoma. METHODS: This retrospective, observational study included patients younger than 65 years with sarcoma who received cisplatin-containing chemotherapy at the Department of Orthopaedic Surgery, Cancer Institute Hospital Ariake, Japan, between January 2011 and December 2020. The evaluated endpoints were the complete response (CR) rate, defined as no emesis and no use of rescue antiemetics, and the no-vomiting rate, defined as no emesis regardless of rescue antiemetic use, in three age groups: children (< 15 years), adolescent and young adult (AYA; ≥15 to < 40 years), and middle age (MA; ≥40 to ≤ 64 years). RESULTS: Twenty patients in the children group, 32 in the AYA group, and 19 in the MA group were included in the analysis. CR rates overall and in the delayed phase were 20% (4/20) in the children group, 28.1% (9/32) in the AYA group, and 42.1% (8/19) in the MA group. CR rates in the acute phase were 70% (14/20) in the children group, 78.1% (25/32) in the AYA group, and 94.7% (18/19) in the MA group. No-vomiting rates overall and in the delayed phase were 50.0% (10/20) in the children group, 59.4% (19/32) in the AYA group, and 78.9% (15/19) in the MA group. No-vomiting rates in the acute phase were 95.0% (19/20) in the children group, 96.9% (31/32) in the AYA group, and 100% (19/19) in the MA group. CONCLUSION: Even in patients younger than 65 years, the risk of CINV seemed higher in younger age groups. TRIAL REGISTRATION: Retrospectively registered.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The Lipid Switch: Ultra-High Dose Omega Fatty Acids Determine MYCN Neuroblastoma Fate and Implicate Substrate-Level Oxylipin Competition. ACS pharmacology & translational science 56.12 2 Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial. Frontiers in oncology 80.36 3 CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy. Frontiers in immunology 51.92 4 Pediatric Spinal Cord Astrocytoma With Granular Cell-Like Morphology and KIAA1549::BRAF Fusion. Neuropathology : official journal of the Japanese Society of Neuropathology 56.4 5 Can O-RADS Be Validated in Children Using a Malignant-Only Cohort? Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 47.5 6 Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders. Cancer chemotherapy and pharmacology 64.3 7 Fertility-related knowledge and childbearing attitudes among female survivors of hematopoietic stem cell transplantation: a cross-sectional study. Journal of cancer survivorship : research and practice 61.1 8 Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies. Journal of gastrointestinal cancer 86.04 9 Focal periphyseal edema with atypical MRI features: Biopsy findings and imaging follow-up. Radiology case reports 56.0 10 CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study. Clinical and translational radiation oncology 83.24 11 Single-session therapeutic plasma exchange as salvage therapy for pegaspargase-induced severe acute pancreatitis accompanied by multiple organ dysfunction in a pediatric patient with B-cell precursor acute lymphoblastic leukemia: a case report. BMC pediatrics 67.0 12 Evaluation of Regulatory B10 Cells in Common Variable Immunodeficiency Patients with and without Autoimmunity. Iranian journal of allergy, asthma, and immunology 59.1 13 An Unexpected Association of a Novel MYOF Variant with Generalized Myopathy and HAE-nl-C1-INH. Iranian journal of allergy, asthma, and immunology 38.6 14 Case Report: CBFA2T3::GLIS2-positive myeloid sarcoma with focal bone marrow involvement mimicking Ewing sarcoma in an infant. Frontiers in oncology 56.6 15 Extended genotype-phenotype spectrum of 17α-hydroxylase/17,20-lyase deficiency: a nine-case series featuring a novel mutation, suspected TART-like lesions, and multisystem involvement. Frontiers in endocrinology 54.5 16 Reninoma in an adolescent boy with negative selective renal vein sampling: a case report and review of the literature. Frontiers in endocrinology 50.3 17 Precision-based exercise protocols for children with cancer: a methodological approach from the European FORTEe research project. Frontiers in pediatrics 76.6 18 CircHIPK3 promotes the progression of B-cell acute lymphoblastic leukemia in children by binding to STAT3. Frontiers in pharmacology 54.3 19 Disease-specific heterogeneity of C-reactive protein across 21 hematologic disorders reflects divergent inflammatory and hematopoietic phenotypes. Frontiers in immunology 76.0 20 Exercise intervention for children with acute leukemia: a best evidence summary. Frontiers in pediatrics 82.2 21 Oral and maxillofacial malignancies in children and adolescents: a 17-year single-center retrospective study. World journal of pediatric surgery 66.9 22 Adult Recurrent Wilms' Tumor Presenting as a Large Mass: A Case Report and Current Literature Review. Sisli Etfal Hastanesi tip bulteni 56.7 23 Exploring beyond the typical Wilms tumor: What a radiologist needs to know. Current problems in diagnostic radiology 60.4 24 The association between the oral microbiome and oral Kaposi's sarcoma-associated herpesvirus (KSHV) shedding is modified by age and HIV status in a rural Ugandan cohort. Journal of oral microbiology 58.0 25 Diagnostic Accuracy and Predictive Factors of Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma: A Systematic Review. Plastic surgery (Oakville, Ont.) 74.5 26 Expanding the Molecular Data of DICER1-Related Tumor Predisposition: Novel Germline Variants in an Argentine Pediatric Cohort. Human mutation 58.0 27 Epidemiology and neurological profiling of vertebral tumors in Mexico: a five-year review from a tertiary referral center. Spinal cord series and cases 63.0 28 A comparison of a novel neuropsychological screening tool with provider recommendations among pediatric cancer survivors. Journal of cancer survivorship : research and practice 61.5 29 Environmental Asbestos Exposure as a Possible Pathway to Early-Onset Pleural Mesothelioma: A Case From Afghanistan and Pakistan to London. Respirology case reports 45.5 30 Clinical consensus guidelines for the management of Noonan syndrome in Japan. Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 74.6 31 Radioiodine or thyroidectomy in children and adolescents with Graves' disease: a structured literature review of efficacy and safety. Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 74.6 32 Genomic characterization of carbapenem-resistant organisms from pediatric patients with hematological malignancies and genomic comparison of infection versus intestinal colonizing strains. Microbiology spectrum 62.9
PATIENT-FRIENDLY SUMMARY

Identification of high-risk age groups for cisplatin-induced nausea and vomiting in young patients with sarcoma.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic